ProNAi Names Polymun as Preferred Manufacturer of PNT2258 DNAi® Based Cancer Therapeutic

News   Jun 15, 2007

 
ProNAi Names Polymun as Preferred Manufacturer of PNT2258 DNAi® Based Cancer Therapeutic
 
 
 

RELATED ARTICLES

Vaccine Against Diabetes Closer Than Ever

News

Scientists at the University of Tampere (Finland) and the Karolinska Institutet (Sweden) have demonstrated that an enterovirus vaccine can protect against virus-induced diabetes in a mouse model for Type 1 diabetes.

READ MORE

Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

News

New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.

READ MORE

New Cell-weighing Technique Helps Predict How Drugs Affect Cancer Cells

News

Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE